$0.85
+0.07 (+9.45%)
Open$0.79
Previous Close$0.78
Day High$0.86
Day Low$0.79
52W High$7.29
52W Low$0.64
Volume—
Avg Volume907.1K
Market Cap77.73M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Hold
17 analysts
Price Target
+1,284.6% upside
Current
$0.85
$0.85
Target
$11.82
$11.82
$9.31
$11.82 avg
$19.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 202.4K | 768.2K | 11.28M |
| Net Income | -80,670,256 | -275,534,081 | 2.04M |
| Profit Margin | -39,009.5% | -37,059.0% | 18.1% |
| EBITDA | -79,951,703 | -288,250,921 | 2.88M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | -73.7% | -73.7% | +22.8% |
| Debt/Equity | 0.01 | 0.01 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |